Treatment of moderate-to-severe and active Graves' orbitopathy: a step forward from the OPTIC study

J Endocrinol Invest. 2020 Oct;43(10):1523-1525. doi: 10.1007/s40618-020-01223-7. Epub 2020 Apr 18.

Authors

M L Tanda¹, D Gallo¹, S Ippolito¹, L Bartalena², E Piantanida¹

Affiliations

¹ Department of Medicine and Surgery, University of Insubria, Endocrine Unit, ASST dei Sette Laghi, Viale Borri, 57, 21100, Varèse, Italy.
² Department of Medicine and Surgery, University of Insubria, Endocrine Unit, ASST dei Sette Laghi, Viale Borri, 57, 21100, Varèse, Italy. luigi.bartalena@uninsubria.it.

PMID: 32306294
DOI: 10.1007/s40618-020-01223-7

No abstract available

Keywords: Exophthalmos; Graves’ disease; Graves’ orbitopathy; IGF-1 receptor; Teprotumumab; Thyroid eye disease.

Publication types

Comment

MeSH terms

Decompression, Surgical
Glucocorticoids
Graves Ophthalmopathy*
Humans

Substances

Glucocorticoids